SCHEMBL6444082

SCHEMBL6444082

COc1ccccc1Oc1ccc(C)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.83
ALDH1A1 P00352 3/20 0.83
MAPK1 P28482 1/20 0.83
L3MBTL1 Q9Y468 1/20 0.83
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA4 P22748 1/20 0.56
CA7 P43166 1/20 0.56
CA9 Q16790 1/20 0.56
CA14 Q9ULX7 1/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
AR P10275 2/20 0.54
HTR2A P28223 2/20 0.53
SLC6A4 P31645 2/20 0.53
ACHE P22303 2/20 0.52
LMNA P02545 2/20 0.51
GAA P10253 2/20 0.50
RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29377831 1.00 HTT (0.83) HTTALDH1A1MAPK1L3MBTL1CA12
SCHEMBL3627857 0.91 HTT (1.00) HTTALDH1A1MAPK1L3MBTL1CA12
SCHEMBL2608310 0.91 HTT (0.65) HTTALDH1A1MAPK1L3MBTL1MEN1
SCHEMBL11585106 0.86 ALDH1A1 (0.60) HTTALDH1A1MAPK1L3MBTL1MEN1
SCHEMBL14191209 0.86 ALDH1A1 (0.91) HTTALDH1A1MAPK1L3MBTL1CA12
SCHEMBL13374189 0.86 L3MBTL1 (0.61) HTTALDH1A1MAPK1L3MBTL1MEN1
SCHEMBL10093724 0.86 L3MBTL1 (0.61) HTTALDH1A1MAPK1L3MBTL1MEN1
SCHEMBL26322497 0.85 L3MBTL1 (0.59) HTTALDH1A1MAPK1L3MBTL1MEN1
SCHEMBL791852 0.84 HTT (0.86) HTTALDH1A1MAPK1L3MBTL1CA12
SCHEMBL10093722 0.82 STS (0.57) HTTALDH1A1MAPK1L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3326715-B1 OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE CE PHARM CO LTD (CN) 2021-09-15 EP disclosed
US-20180207628-A1 OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2018-07-26 US disclosed
US-20180207628-A1 OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2018-07-26 US disclosed
EP-3326715-A1 OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) 2018-05-30 EP disclosed
US-9624239-B2 Protein kinase inhibitors PHARMASCIENCE INC. (CA) 2017-04-18 US disclosed
WO-2017012379-A1 OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE 中国科学院上海有机化学研究所 2017-01-26 WO disclosed
US-20140045833-A1 Protein Kinase Inhibitors PHARMASCIENCE INC. (CA) 2014-02-13 US disclosed
US-20120149706-A1 INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS DUMAS JACQUES (US) 2012-06-14 US disclosed
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas DUMAS JACQUES (US) 2012-05-24 US disclosed
US-20120046290-A1 INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2012-02-23 US disclosed
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 US disclosed
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 US disclosed
US-20050054882-A1 Diaryl ether condensation reactions NSF - DEITR 2005-03-10 US disclosed
US-6762329-B2 EFFECTS OF ACIDIC ACTIVATORS ON ULLMANN-TYPE COUPLINGS INVOLVING ELECTRON-POOR AND/OR RELATIVELY INSOLUBLE SUBSTRATES. MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2004-07-13 US disclosed
US-20030088128-A1 Diaryl ether condensation reactions NATIONAL SCIENCE FOUNDATION 2003-05-08 US disclosed
US-6395939-B1 CATALYTIC ETHERIFICATION AND CONDENSATION WITH COPPER CATALYSTS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2002-05-28 US disclosed
WO-1999018057-A1 PREPARATION OF DIARYL ETHER BY CONDENSATION REACTIONS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1999-04-15 WO disclosed
EP-0428385-A1 Cholesterol ester hydrolase inhibitors AMERICAN HOME PRODUCTS CORPORATION (US) 1991-05-22 EP disclosed
US-4113782-A CATALYTIC OXIDATION AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 1978-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149706-A1 INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS MAPK1, MAP3K1, MAP3K7 HTT 3103/4885ALDH1A1 1451/4885MAPK1 1/4885
US-20050054882-A1 Diaryl ether condensation reactions NSFL1C, DERL1, UBE2M HTT 3396/4885ALDH1A1 1863/4885MAPK1 3196/4885
US-20120046290-A1 INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS MAPK1, MAP3K1, MAP3K7 HTT 3103/4885ALDH1A1 1451/4885MAPK1 1/4885
US-20030088128-A1 Diaryl ether condensation reactions NSFL1C, DERL1, UBE2M HTT 3396/4885ALDH1A1 1863/4885MAPK1 3196/4885
US-20140045833-A1 Protein Kinase Inhibitors LCK, BTK, TEC HTT 4197/4885ALDH1A1 4846/4885MAPK1 159/4885
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BRAF, RAF1, ARAF HTT 3520/4885ALDH1A1 2759/4885MAPK1 148/4885
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas BRAF, RAF1, ARAF HTT 3520/4885ALDH1A1 2759/4885MAPK1 148/4885
US-20180207628-A1 OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE AOC2, AOC1, AOC3 HTT 3183/4885ALDH1A1 213/4885MAPK1 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.